Kangyuan Pharmaceutical (600557.SH) received the clinical trial approval notice for Shiwei Anchang Granules.

Zhitong Finance APP News, Kangyuan Pharmaceutical (600557.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" for Shiwei Anchang Granules issued by the National Medical Products Administration. Shiwei Anchang Granules is a clinical experience formula formed under the guidance of traditional Chinese medicine theory, with the effects of strengthening the spleen and clearing the intestines, astringing the intestines and stopping diarrhea, and is clinically used for ulcerative colitis caused by spleen deficiency and dampness accumulation.